iSAM Funds UK Ltd Purchases Shares of 45,335 Henry Schein, Inc. $HSIC

iSAM Funds UK Ltd purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, Holdings Channel reports. The fund purchased 45,335 shares of the company’s stock, valued at approximately $3,009,000.

Several other large investors have also recently made changes to their positions in the stock. MAI Capital Management boosted its position in shares of Henry Schein by 7.5% during the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock worth $137,000 after purchasing an additional 144 shares during the period. CW Advisors LLC lifted its stake in Henry Schein by 2.8% during the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after purchasing an additional 163 shares in the last quarter. Truist Financial Corp lifted its stake in Henry Schein by 3.3% during the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after purchasing an additional 175 shares in the last quarter. Claret Asset Management Corp boosted its position in shares of Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after buying an additional 187 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Henry Schein by 1.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after buying an additional 229 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Trading Up 0.8%

NASDAQ HSIC opened at $75.57 on Friday. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The firm has a 50 day moving average of $78.21 and a two-hundred day moving average of $72.83. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $8.67 billion, a PE ratio of 23.11, a price-to-earnings-growth ratio of 2.22 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other Henry Schein news, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stanley M. Bergman sold 43,812 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the transaction, the chief executive officer owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. The trade was a 10.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 104,556 shares of company stock worth $8,476,351. Insiders own 1.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HSIC. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. UBS Group upped their target price on shares of Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Barclays began coverage on shares of Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target for the company. Finally, Morgan Stanley upped their price objective on Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.